The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma.

Aims: Abnormalities in HER2 are well-established oncogenic drivers and are approved therapeutic targets in various malignancies. Prior studies evaluating HER2 expression in prostate cancer (PCa) have yielded variable results. Most of these studies used immunohistochemistry scoring systems based on breast cancer data.

Why African Americans say "No": A Study of Pharmacogenomic Research Participation.

Objective: To identify reasons for nonparticipation by African Americans in cardiovascular pharmacogenomic research.

Design: Prospective, open-ended, qualitative survey.

Setting: Research staff approached patients eligible for the Discovery Project of The African American Cardiovascular pharmacogenomics CONsorTium in the inpatient or outpatient setting at four different institutions during September and October 2018.